BHP Group Limited (BHP): The federal reserve notes being sold are...

The federal reserve notes being sold are junk.

Saving Grace · 2021-09-03T15:22:34.2900000Z

The federal reserve notes being sold are junk. The Federal Reserve is privatized and already BK. The Quantum Financial system is taking over and the fiat petrol dollar days are over while the U.S. returns to the gold standard. Not a good time to buy anything secured by the Fed as the Fed is no longer secure.

Play Episode

7min

Proactive - Interviews for investors

Chesnara CEO discusses strong 2024 results, dividend growth and M&A outlook

Chesnara PLC (LSE:CSN) CEO Steve Murray talked to Proactive's Stephen Gunnion about the company’s strong 2024 full-year results, highlighting robust cash generation and consistent dividend growth. Murray highlighted that Chesnara generated £60 million in cash over the year, providing strong dividend coverage and supporting its 20-year track record of uninterrupted dividend growth. The business also increased its overall value and maintained a strong solvency position. The interview also covered Chesnara’s acquisition strategy, with Murray detailing the second Canada Life deal, which delivered an uplift in economic value to £11 million—higher than the £8 million initially expected—off a £2 million consideration. He explained that Chesnara currently holds around £200 million in acquisition firepower, supported by a solvency capital ratio of 203%. Murray described the current M&A pipeline as “positive,” noting that a reduction in private equity competition is opening up new opportunities in the UK and Benelux. He also commented on broader macroeconomic conditions, noting that despite some volatility, Chesnara’s long-term outlook remains stable due to natural hedges and long-duration contracts. Looking ahead to 2025, Murray reiterated Chesnara’s confidence in maintaining dividend growth, underpinned by strong visibility on future cash flows well above required commitments. For more CEO interviews and investor insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and hit the notification bell so you never miss an update. #Chesnara #InsuranceStocks #DividendGrowth #MergersAndAcquisitions #CashGeneration #UKStocks #BeneluxMarkets #CanadaLifeDeal #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Genflow Biosciences CEO welcomes new investment; outlines dog longevity trial

Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about a pivotal new direction for the company as it initiates a clinical trial focused on improving aging in dogs. Leire described the trial as a natural evolution from Genflow's previous success in mice, noting the commercial appeal of the canine market. “There is nothing to improve really the quality of life of our aging dogs,” he said, adding that the study meets a significant unmet need. The trial will run for one year, with six months of treatment followed by six months of assessment. It's being managed by independent contract research organisation Syngene. Leire emphasised the scientific rigour of the trial, which is controlled, randomised and includes both aesthetic and biological endpoints. These include coat quality, mitochondrial function, and methylation clocks — all of which have potential crossover value for human applications. Leire also highlighted the company’s differentiated approach compared to US competitors using repurposed drugs like metformin. Genflow, he said, is pursuing gene therapy with the potential for greater impact. The investment supporting the trial, although limited in size, is seen as a strategic vote of confidence, bringing in credible investors from outside the UK, including the US. Leire described the initiative as a major step that could generate near-term revenue and redefine the company’s biotech positioning. For more company updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future content. #GenflowBiosciences #GeneTherapy #DogAging #BiotechInvestment #LongevityResearch #Mitochondria #PetHealth #ClinicalTrials #AgingDogs #BiotechNews

Proactive - Interviews for investors

SomnoMed lifts revenue 19% amid soaring demand

SomnoMed CO-CEOs Amrita Blickstead and Karen Borg talked with Proactive about the company’s performance and opportunities in the global sleep apnea treatment market. The company, which develops proprietary oral appliances for obstructive sleep apnea, is seeing significant demand as patients seek alternatives to traditional CPAP therapy. “About 60% of people fail to be able to use actual CPAP therapy because it’s quite invasive,” Borg explained. SomnoMed’s devices offer a less intrusive solution and are distributed through dental channels in 28 countries, with strong uptake in the United States and Western Europe. The co-CEOs discussed a major tailwind from the rising use of GLP-1 therapies for weight loss, which is pushing more patients to explore alternative sleep apnea treatments. Increased public awareness of sleep wellness through apps and consumer health trends is also fueling demand. To meet this growth, Blickstead said their immediate focus was on ensuring “the right foundation for profitable growth.” This included strengthening the company’s financial base, reducing costs, paying down debt, and investing heavily in manufacturing. Production capacity has increased by over 40%, with revenue up 19% year-on-year and EBITDA for the first half reaching AUD 5.80 million, compared to a AUD 1.10 million loss previously. Despite these gains, Blickstead noted they are still “chasing our tails and trying to make enough product to continue to grow this business.” #SomnoMed #SleepApnea #OralAppliance #HealthcareInnovation #CPAPAlternative #GLP1 #SleepTech #MedicalDevices #HealthInvesting #ProactiveInvestors

Proactive - Interviews for investors

Cuscal FY25 update: profit grows on stable volumes

Cuscal Limited Managing Director Craig Kennedy talked with Proactive at AIM's Small and MIdcap conference about the company’s role in Australia's financial infrastructure and its recent financial performance for the first half of FY25. Kennedy explained that Cuscal is one of only five organisations in Australia with the full suite of licensing, infrastructure, and capabilities required to offer end-to-end payment services—alongside the four major banks. The company serves a range of clients including other banks, corporates, and fintechs, as well as working with NAB’s UBank division. Kennedy emphasised Cuscal’s position as a “neutral, independent” access point to payment infrastructure. On financial performance, Kennedy said Cuscal expects to “modestly exceed the forecast in the prospectus” issued at the time of its IPO in November. He noted that the business enjoys stable, predictable revenue and has completed significant investment in areas like real-time payments and operational upgrades. As a result, the company is beginning to see operational leverage. Kennedy stated: “Mid to high single digit volume growth will translate to low double digit profit growth.” He said H1 FY25 results showed 7% volume growth and between 12% to 13% profit growth. Reflecting on sector innovation, Kennedy described Cuscal as an "airport" enabling new players—like fintechs—to create and deliver new customer experiences on top of a stable infrastructure. He also said investors view the company as a “safe harbour,” appreciating its unique market position and stable growth outlook. #Cuscal #ASXStocks #FintechAustralia #PaymentsInfrastructure #CraigKennedy #InvestorUpdates #RealTimePayments #ASXConference #FinancialServices #BankingInnovation

Followers	111
Posts	12401
Boards Moderated	3
Alias Born	01/29/2015

Volume:	2,283,462
Day Range:	47.30 - 48.53
Bid:
Ask:
Last Trade Time:	3:23:17 PM EDT
Total Trades:	31,134

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BHP Detailed Quote

Recent BHP News

More BHP News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BHP News

Go Ad-Free